Notably, the surrogate anti-TIM-3 mAb that showed effectiveness in inhibiting leukemic engraftment in an immune-deficient murine host was both ADCC-competent and CDC-competent, indicating that optimization of FcR engagement may be a desirable characteristic for anti-TIM-3 mAbs in AML/MDS [21,22]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.